Attached files

file filename
8-K - FORM 8-K - ORGANOVO HOLDINGS, INC.d443362d8k.htm
Changing the Shape of
Medical Research
and Practice
Keith Murphy
Chairman and Chief Executive Officer
0
©
Copyright 2012, Organovo Holdings, Inc.  This report is solely for the use of intended audience.  No part
of it may be circulated, quoted, or reproduced for distribution outside the organization without prior
written approval from Organovo Holdings, Inc.
Exhibit 99.1
November 23, 2012


SAFE HARBOR STATEMENT
1
©
Copyright 2012  Organovo Holdings, Inc.
OTC QX: ONVO
This
presentation
contains
“forward-looking
statements”
that
involve
significant
risks
and
uncertainties.
All
statements
other
than
statements
of
historical
fact
are
statements
that
could
be
deemed
forward-looking
statements,
including,
but
not
limited
to,
statements
regarding
the
results
and
benefits
of
the
Company’s
tender
offer
and
its
prospective
performance,
opportunities
and
business
outlook.
Any
forward-looking
statements
contained
herein
are
based
on
current
expectations,
but
are
subject
to
a
number
of
risks
and
uncertainties.
The
risks
and
uncertainties
that
could
cause
the
Company’s
actual
future
results
to
differ
materially
from
current
expectations
include,
but
are
not
limited
to,
risks
and
uncertainties
relating
to
the
Company's
ability
to
develop,
market
and
sell
products
based
on
its
technology;
the
expected
benefits
and
efficacy
of
the
Company’s
products
and
technology;
the
availability
of
substantial
additional
funding
for
the
Company
to
continue
its
operations
and
to
conduct
research
and
development,
clinical
studies
and
future
product
commercialization;
the
Company's
failure
to
achieve
its
business,
research,
product
development,
regulatory
approval,
marketing
and
distribution
plans
and
strategies;
and
the
successful
completion
of
the
tender
offer.
These
and
other
factors
are
identified
and
described
in
more
detail
in
the
Company’s
filings
with
the
SEC,
including
its
current
report
on
Form
8-K/A
filed
with
the
SEC
on
May
11,
2012.
These
forward-looking
statements
are
made
as
of
the
date
of
this
presentation,
and
the
Company
does
not
undertake an obligation to update these forward-looking statements after such date.


2
©
Copyright 2012  Organovo Holdings, Inc.


3
Organovo has made tremendous progress
In past 12 months
Signed up United Therapeutics
Delivered tissue blocks to Pfizer under our collaboration
NIH Grant for 3D liver
Successful financing and reverse merger
Attracted top executives and doubled staff
Opened 15,000 sq ft new facility
Completed Phase 1 market research
OTC QX uplist
©
Copyright 2012  Organovo Holdings, Inc.


4
Market research reveals opportunity
Cell Assay Products
Identified specific market opportunity >$500M by 2018
High unmet customer need and market opportunity
identified that can be met with 3D cell assay products
Overall cell biology market growing to $17B by 2016,
12% CAGR
Disease models
Qualitative market research conducted to target initial
opportunities –
including Oncology
Focus on Pharma co. “lead optimization”
as entry point
©
Copyright 2012  Organovo Holdings, Inc.
Source: 2012 Scientia Advisors market research, sponsored by Organovo


5
Organovo milestones in 2013
Organovo will keep delivering
Major new data on 3D liver by Q2 2013
Expanding the set of current partners
Reaching upstream in drug discovery to partner with
academics –
now pursuing partnerships
Technology partnerships to develop bioprinting
Collaborate with 3D peers in non-bio spaces
Company pursuing uplisting to NASDAQ or NYSE
©
Copyright 2012  Organovo Holdings, Inc.


6
Goals of tender offer
Clean up derivative liability
Outstanding warrants from Q1 offering create derivative
liability for company
Company currently is below shareholder equity
requirements for listing on NASDAQ or NYSE MKT
as a result
Raise funds
End Q3 Cash on hand $7.7M
Tender offer can raise up to $11.5M gross
Company net burn of ~$7-8M/year expected in 2013
Source: Scientia Advisors study, commissioned by company
©
Copyright 2012  Organovo Holdings, Inc.


Seeking uplisting to major exchange
7


Seeking uplisting to major exchange
8
NYSE MKT Initial Listing Standards


Organovo Contacts:
Keith Murphy, CEO
(858) 550-9993
kmurphy@organovo.com
Barry Michaels, CFO
(858) 224-1003
bmichaels@organovo.com
Website: 
http://www.organovo.com
9
Enabling tissue on demand
OTC QX: ONVO
©
Copyright 2012  Organovo Holdings, Inc.